The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Enzyme-Induced and Tumor-Targeted Drug Delivery System Based on Multifunctional Mesoporous Silica Nanoparticles
Abstract
Functional mesoporous silica particles have attracted growing research interest for controlled drug delivery in targeted cancer therapy. For the purpose of efficient targeting tumor cells and reducing the adverse effect of antitumor drug doxorubicin (DOX), biocompatible and enzyme-responsive mesoporous silica nanoparticles (MSNs) with tumor specificity were desired. To construct these functional MSNs, the classic rotaxane structure formed between alkoxysilane tether and α-cyclodextrin (α-CD) was employed to anchor onto the orifices of MSNs as gatekeeper in this work. After subsequent modification by multifunctional peptide (azido-GFLGR7RGDS with tumor-targeting, membrane-penetrating, and cathepsin B-responsive functions) to stabilize the gatekeeper, the resulting functional MSNs showed a strong ability to load and seal DOX in their nanopores. When incubating these DOX-loaded MSNs with tumor and normal cells, the nanoparticles could efficiently employ their surface-encoded RGDS and continuous seven arginine (R7) sequences to target tumor cells, penetrate the cell membrane, and enter tumor cells. Because cathepsin B overexpressed in late endosomes and lysosomes of tumor cells could specifically hydrolyze GFLG sequences of the nanovalves, the DOX-loaded MSNs showed an "off-on" drug release behavior that ∼80% loaded DOX could be released within 24 h and thus showed a high rate of apoptosis. Furthermore, in vitro cellular experiments indicated that DOX-loaded MSNs (DOX@MSN-GFLGR7RGDS/α-CD) had high growth inhibition toward αvβ3-positive HeLa cancerous cells. The research might offer a practical way for designing the tumor-targeted and enzyme-induced drug delivery system for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,836
Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆
SLOWING, I., VIVEROESCOTO, J., WU, C., & LIN, V (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.012 · Cited by 2,653
Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids
FIELDS, G. B., & NOBLE, R. L. (1990) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1990.tb00939.x · Cited by 2,493
Mesoporous silica nanoparticles in biomedical applications
Li, Z., Barnes, J. C., Bosoy, A., Stoddart, J. F., & Zink, J. I. (2012) · Chemical Society Reviews · doi:10.1039/c1cs15246g · Cited by 1,907
Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery
Vivero‐Escoto, J. L., Slowing, I. I., Trewyn, B. G., & Lin, V. S. ‐. (2010) · Small · doi:10.1002/smll.200901789 · Cited by 998
Zhao, Y., Trewyn, B. G., Slowing, I. I., & Lin, V. S.-Y. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901831u · Cited by 771
Lee, J. E., Lee, N., Kim, H., Kim, J., Choi, S. H., Kim, J. H., Kim, T., Song, I. C., Park, S. P., Moon, W. K., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja905793q · Cited by 707
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Cited by
Mesoporous Silica Nanoparticles for Drug Delivery
Manzano, M., & Vallet‐Regí, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201902634 · Cited by 939
Carbon-Based Nanomaterials for Biomedical Applications: A Recent Study
Maiti, D., Tong, X., Mou, X., & Yang, K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01401 · Cited by 733
Mesoporous silica nanoparticles for drug and gene delivery
Zhou, Y., Quan, G., Wu, Q., Zhang, X., Niu, B., Wu, B., Huang, Y., Pan, X., & Wu, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.007 · Cited by 706
Self-citationEngineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Wankar, J., Kotla, N. G., Gera, S., Rasala, S., Pandit, A., & Rochev, Y. A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909049 · Cited by 486
Metadata
- Authors
- Cheng, Y.-J., Luo, G.-F., Zhu, J.-Y., Xu, X.-D., Zeng, X., Cheng, D.-B., Li, Y.-M., Wu, Y., Zhang, X.-Z., Zhuo, R.-X., & He, F.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-04-24
- Volume
- 7
- Issue
- 17
- Pages
- 9078-9087
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W2058022874
- Cited by
- 253
- References
- 36
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enzyme-Induced and Tumor-Targeted Drug Delivery System Based on Multifunctional Mesoporous Silica Nanoparticles. https://app.cochat.ai/papers/10.1021/acsami.5b00752
- The paper
- Cheng, Y.-J., Luo, G.-F., Zhu, J.-Y., Xu, X.-D., Zeng, X., Cheng, D.-B., Li, Y.-M., Wu, Y., Zhang, X.-Z., Zhuo, R.-X., & He, F. (2015). Enzyme-Induced and Tumor-Targeted Drug Delivery System Based on Multifunctional Mesoporous Silica Nanoparticles. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5b00752
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.